(25 days)
No
The device description and performance studies focus on the physical and functional aspects of a cardiotomy reservoir, with no mention of AI or ML technologies.
No
The device is described as a cardiotomy reservoir for defoaming, filtering, and storing blood during cardiopulmonary bypass procedures, and it does not actively treat or mitigate a disease or condition.
No.
The device is a cardiotomy reservoir used to defoam, filter, and store blood during cardiovascular procedures. It does not provide any diagnostic information or interpret patient data.
No
The device is a physical cardiotomy reservoir, a hardware component used in cardiovascular procedures. The description details its physical design, materials, and testing related to biocompatibility and mechanical performance, not software functionality.
Based on the provided text, the CARD 43 is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly describes the device's function in collecting, defoaming, filtering, and storing blood from the operating field during surgical procedures (cardiopulmonary bypass and chest drainage). This is a direct interaction with the patient's blood within the body's system during or immediately after a medical procedure.
- Device Description: The description reinforces this by stating it handles blood aspirated from the operative field.
- Lack of IVD Characteristics: IVD devices are typically used to examine specimens (like blood, urine, tissue) outside the body to provide information for diagnosis, monitoring, or screening. The CARD 43's function is not for analyzing or testing the blood for diagnostic purposes. It's a component of a surgical system for managing blood during and after a procedure.
- Performance Studies: The performance studies focus on biocompatibility, structural integrity, filtration efficiency, and other aspects related to handling blood within the extracorporeal circuit, not on diagnostic accuracy or analytical performance.
Therefore, the CARD 43 is a medical device used in a surgical setting, but it does not fit the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The CARD 43 is a cardiotomy reservoir specifically designed for cardiovascular procedures requiring cardiopulmonary by-pass. It defoams, filters and stores the blood from the operating field through thoracic, intracardiac and general suction. CARD 43 can be used postoperatively for chest drainage. The CARD 43 should not be used longer than 6 hours. Contact with blood for longer periods is not advised.
Product codes
DTN
Device Description
The CARD 43 Cardiotomy Reservoir with phosphoryIcholine coating is intended for use in cardiovascular procedures requiring cardiopulmonary by-pass. It defoams, filters and stores the blood coming from the operating field through thoracic, intracardiac and general suction. The device is a modified version of the currently marketed Synthesis R (K022450). The design modifications consist of: eliminating the venous return inlet connector on the top of the reservoir lid. eliminating the venous section of the filtering system and updating of product specifications in the IFU. The modification enables the device to be suited for filtration, defoaming and collection only of blood aspirated from the operative field during cardiopulmonary bypass procedures or postoperatively during chest drainage. Other than this change the CARD 43 and the Synthesis R are similar in their intended use, materials and manufacturing processes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
NON CLINICAL TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:2003 and the FDA May 1, 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the CARD 43. The aged device was tested for Hemolysis, Cytotoxicity, Irritation, Acute Systemic Toxicity and Mutagenicity, Sterility, Pyrogenicity, ETO residuals. Package integrity testing was also conducted. The results testing met established specifications.
IN VITRO TEST RESULTS:
In vitro testing was carried out in accordance with the requirements of "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000 - and when applicable, following the ISO 15674 (2001) standard for "Cardiovascular Implants and Artificial Organs - Hardshell Cardiotomies/Venous Reservoirs Systems (with/without filter) and Soft Venous Reservoir Bags" for providing the data necessary to demonstrate both the substantial equivalence with the unmodified device and also for complying with safety and effectiveness requirements. The aged device was tested for in vitro hemolysis/cell depletion, structural integrity, mechanical integrity, breakthrough times and volumes, reservoir graduated scale accuracy, residual blood volume, defoaming capacity, filtration efficiency and flaking and leaching studies characterization. The results of these tests met established specifications. This 510(k) cross-references performance data previously submitted in the original Synthesis R 510(k) (K022450) as the above mentioned aspects are not affected by the modification.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
0
Sorin Group Italia S.r.I. CARD 43 Cardiotomy Reservoir Special 510(k): Device Modificatio June 1, 2006
JUN 27 2006
510(k) SUMMARY
SUBMITTER:
CONTACT PERSON:
Luigi Vecchi Phone: 011 39 0535 29811 Fax: 011 39 0535 25229
June 1, 2006
Sorin Group Italia S.r.I.
- Via Statale 12 Nord 41037 Mirandola (MO) Italy
DATE PREPARED:
DEVICE TRADE NAME:
COMMON NAME:
CLASSIFICATION NAME:
UNMODIFIED DEVICE
CARD 43 Cardiotomy Reservoir with phosphorvicholine coating (hereafter referred to as CARD 43)
Hardshell Cardiotomy Reservoir
Cardiopulmonary Bypass Blood Reservoir / Cardiopulmonary Bypass Defoamer
Synthesis R Hardshell Venous/Cardiotomy Reservoir Mimesys Treated with phosphoryIcholine coating (hereafter referred to as Synthesis R) (K022450)
DEVICE DESCRIPTION:
The CARD 43 Cardiotomy Reservoir with phosphoryIcholine coating is intended for use in cardiovascular procedures requiring cardiopulmonary by-pass. It defoams, filters and stores the blood coming from the operating field through thoracic, intracardiac and general suction. The device is a modified version of the currently marketed Synthesis R (K022450). The design modifications consist of: eliminating the venous return inlet connector on the top of the reservoir lid. eliminating the venous section of the filtering system and updating of product specifications in the IFU. The modification enables the device to be suited for filtration, defoaming and collection only of blood aspirated from the operative field during cardiopulmonary bypass procedures or postoperatively during chest drainage. Other than this change the CARD 43 and the Synthesis R are similar in their intended use, materials and manufacturing processes.
1
INDICATION FOR USE:
The CARD 43 is a cardiotomy reservoir specifically designed for cardiovascular procedures requiring cardiopulmonary by-pass. It defoams, filters and stores the blood from the operating field through thoracic, intracardiac and general suction. CARD 43 can be used postoperatively for chest drainage. The CARD 43 should not be used longer than 6 hours. Contact with blood for longer periods is not advised.
TECHNOLOGICAL CHARACTERISTICS:
The CARD 43 is similar to the Synthesis R unmodified device with respect to intended use, materials, biocompatibility and performance of the PC coating, operating principles, control mechanisms, fundamental scientific technology and manufacturing process. The hardshell cardiotomy/venous reservoir of both CARD 43 and Synthesis R share the same technological characteristics, operating principles, and materials except for the design change. The design modifications consist of: eliminating the venous return inlet connector on the top of the reservoir lid, eliminating the venous section of the filtering system and updating of product specifications in the IFU. These design changes make the CARD 43 primarily suited for the collection and removal of microemboli or microaggregates from suctioned blood. The use during cardiopulmonary procedures or postoperatively for chest drainage remains unchanged as a result of the modification. The CARD 43 is substantially equivalent to Synthesis R in intended use, patient population and performance specifications.
The coating of the CARD 43 is identical to the phosphorylcholine coating used on Synthesis R. The cardiotomy reservoir is ethylene oxide sterilized and has a nonpyrogenic fluid path. It is for single use only.
NON CLINICAL TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:2003 and the FDA May 1, 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the CARD 43. The aged device was tested for Hemolysis, Cytotoxicity, Irritation, Acute Systemic Toxicity and Mutagenicity, Sterility, Pyrogenicity, ETO residuals. Package integrity testing was also conducted. The results testing met established specifications.
2
IN VITRO TEST RESULTS:
In vitro testing was carried out in accordance with the requirements of "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000 - and when applicable, following the ISO 15674 (2001) standard for "Cardiovascular Implants and Artificial Organs - Hardshell Cardiotomies/Venous Reservoirs Systems (with/without filter) and Soft Venous Reservoir Bags" for providing the data necessary to demonstrate both the substantial equivalence with the unmodified device and also for complying with safety and effectiveness requirements. The aged device was tested for in vitro hemolysis/cell depletion, structural integrity, mechanical integrity, breakthrough times and volumes, reservoir graduated scale accuracy, residual blood volume, defoaming capacity, filtration efficiency and flaking and leaching studies characterization. The results of these tests met established specifications. This 510(k) cross-references performance data previously submitted in the original Synthesis R 510(k) (K022450) as the above mentioned aspects are not affected by the modification.
CONCLUSIONS:
The CARD 43 device performs in a manner substantially equivalent to the unmodified device with respect to biocompatibility and the functional parameters in common with the unmodified device. Additional testing has also demonstrated the effectiveness of production techniques to assure that the device is sterile and non-pyrogenic.
3
Image /page/3/Picture/11 description: The image shows a logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of three stylized, curved lines that appear to be stacked on top of each other.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 2 7 2006
Sorin Group Italia S.R.L. c/o Mr. Barry Sall Principal Consultant 200 West Street Waltham, MA 02451
Re: K061527
CARD 43 Cardiotomy Reservoir with PhosphoryIcholine Coating Regulation Number: 21 CFR 870.4400 Regulation Name: Cardiopulmonary Bypass Reservoir Regulatory Class: Class II (Two) Product Code: DTN Dated: June 1. 2006 Received: June 2, 2006
Dear Mr. Sall:
We have reviewed your Section 510(k) premarket notification of intent to market the referenced above and have determined the device is substantially equivalent (for the use stated in the enclosure) to legally marketed predicate devices marketed in interstat prior to May 28, 1976, the enactment date of the Medical Device Amedical Ministant Mar have been reclassified in accordance with the provisions of the Federal Food. Drug, or crud ( osme to Act (Act) that do not require approval of a premarket approval application (PMA). Tour Close therefore, market the device, subject to the general controls provisions of the Act. The sector. controls provisions of the Act include requirements for annual registration. Institions good manufacturing practice. labeling, and prohibitions against misbranding and additeration.
If your device is classified (see above) into cither class II (Special Controls) or class III (PM. A. it may be subject to such additional controls. Existing major regulations affècting your levyce an be found in the Code of Federal Regulations. Title 21. Paris 800 to 898. In addition, FDA may partish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. Barry Sall
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Duna R. Virdner
Image /page/4/Picture/6 description: The image shows a signature on the left and the letters 'B' and 'D' on the right. The signature is illegible, but it appears to be written in cursive. The letters 'B' and 'D' are in a simple, sans-serif font. The image is simple and contains only a few elements.
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Image /page/5/Picture/0 description: The image shows the logo for Sorin Group, a medical technology company. The logo features a stylized graphic to the left of the company name. Below the company name is the tagline "At the heart of medical technology". The logo is simple and professional, and it conveys the company's focus on medical technology.
.
Sorin Group Italia S.r.I.
510(k) Number (if known): K661527
Device Name: CARD 43 Cardiotomy Reservoir with PhosphoryIcholine Coating Indications for Use:
The CARD 43 is a cardiotomy reservoir specifically designed for cardiovascular procedures requiring cardiopulmonary by-pass. It defoams, filters and stores the blood from the operating field through thoracic, intracardiac and general suction. CARD 43 can be used postoperatively for chest drainage. The Card 43 should not be used longer than 6 hours. Contact with blood for longer periods is not advised.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-the-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Duna R. Vichnes
sign-Off
levices
Number K061527